Merz Pharms Drug Patent Portfolio
Merz Pharms owns 3 orange book drugs protected by 26 US patents Given below is the list of Merz Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8545878 | Capsules containing high doses of levodopa for pulmonary use | 16 Nov, 2032 | Active |
| US8685442 | Capsules containing high doses of levodopa for pulmonary use | 16 Nov, 2032 | Active |
| US8945612 | Capsules containing high doses of levodopa for pulmonary use | 16 Nov, 2032 | Active |
| US9393210 | Capsules containing high doses of levodopa for pulmonary use | 16 Nov, 2032 | Active |
| USRE43711 | Pulmonary delivery for levodopa | 03 Feb, 2029 | Active |
| US8007826 | Sustained release aminopyridine composition | 26 May, 2027 | Active |
| US8354437 | Method of using sustained release aminopyridine compositions | 22 Dec, 2026 | Active |
| US8440703 | Methods of using sustained release aminopyridine compositions | 08 Apr, 2025 | Active |
| US8663685 | Sustained release aminopyridine composition | 18 Jan, 2025 | Active |
| US9918973 | Sustained release aminopyridine composition | 13 Dec, 2024 | Expired |
| US7182961 | Particulate compositions for pulmonary delivery | 22 Feb, 2024 | Expired |
| US7638552 | Method for increasing the bioavailability of glycopyrrolate | 20 Aug, 2023 | Expired |
| US7816396 | Method for increasing the bioavailability of glycopyrrolate | 20 Aug, 2023 | Expired |
| US8404276 | Pulmonary delivery for levodopa | 19 Mar, 2023 | Expired |
| US8586093 | Pulmonary delivery for levodopa | 19 Mar, 2023 | Expired |
| US9155699 | Pulmonary delivery for levodopa | 19 Mar, 2023 | Expired |
| US7384649 | Particulate compositions for pulmonary delivery | 20 Nov, 2022 | Expired |
| US6858199 | High efficient delivery of a large therapeutic mass aerosol | 04 Nov, 2021 | Expired |
| US7556798 | Highly efficient delivery of a large therapeutic mass aerosol | 04 Nov, 2021 | Expired |
| US7146978 | Inhalation device and method | 16 Apr, 2021 | Expired |
| US6514482 | Pulmonary delivery in treating disorders of the central nervous system | 19 Sep, 2020 | Expired |
| US6613308 | Pulmonary delivery in treating disorders of the central nervous system | 19 Sep, 2020 | Expired |
| US6979437 | Pulmonary delivery in treating disorders of the central nervous system | 19 Sep, 2020 | Expired |
| US6921528 | Highly efficient delivery of a large therapeutic mass aerosol | 19 Jun, 2020 | Expired |
| US8628754 | Highly efficient delivery of a large therapeutic mass aerosol | 19 Jun, 2020 | Expired |
| US5540938 | Formulations and their use in the treatment of neurological diseases | 30 Jul, 2018 | Expired |
Latest Legal Activities on Merz Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Merz Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jan, 2024 | US9393210 |
|
Expire Patent
Critical
| 20 Nov, 2023 | US9155699 |
|
Maintenance Fee Reminder Mailed
Critical
| 05 Jun, 2023 | US9155699 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Feb, 2023 | US8007826 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Apr, 2022 | US7816396 |
|
Expire Patent
Critical
| 21 Feb, 2022 | US8628754 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Sep, 2021 | US9918973 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Sep, 2021 | US8663685 |
|
Maintenance Fee Reminder Mailed
Critical
| 06 Sep, 2021 | US8628754 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Jun, 2021 | US7638552 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 May, 2021 | US8586093 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 17 Mar, 2021 | US8545878 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Dec, 2020 | US7556798 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Nov, 2020 | US8440703 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Sep, 2020 | US8404276 |
Merz Pharms's Drug Patent Litigations
Merz Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 27, 2004, against patent number US7556798. The petitioner , challenged the validity of this patent, with David A. Edwards et al as the respondent. Click below to track the latest information on how companies are challenging Merz Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8007826 | September, 2015 |
FWD Entered
(09 Mar, 2017)
| Acorda Therapeutics, Inc. | Coalition For Affordable Drugs (ADROCA) LLC |
| US8354437 | September, 2015 |
FWD Entered
(09 Mar, 2017)
| Acorda Therapeutics, Inc. | Coalition for Affordable Drugs (ADROCA) LLC |
| US8440703 | September, 2015 |
FWD Entered
(09 Mar, 2017)
| Acorda Therapeutics, Inc. | Coalition For Affordable Drugs (ADROCA) LLC |
| US8663685 | September, 2015 |
FWD Entered
(09 Mar, 2017)
| Acorda Therapeutics, Inc. | Coalition For Affordable Drugs (ADROCA) LLC |
| US8007826 | February, 2015 |
Terminated-Denied
(24 Aug, 2015)
| Acorda Therapeutics, Inc. | Coalition for Affordable Drugs (ADROCA) LLC |
| US8663685 | February, 2015 |
Terminated-Denied
(24 Aug, 2015)
| Acorda Therapeutics, Inc. | Coalition for Affordable Drugs (ADROCA) LLC |
| US7556798 | May, 2007 |
Decision
(18 Aug, 2008)
| David A. Edwards et al | |
| US7556798 | August, 2004 |
Decision
(18 Mar, 2005)
| David A. Edwards et al | |
Merz Pharms's Family Patents
Merz Pharms drugs have patent protection in a total of 22 countries. It's US patent count contributes only to 24.1% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Merz Pharms Drug List
Given below is the complete list of Merz Pharms's drugs and the patents protecting them.
1. Ampyra
Ampyra is protected by 6 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8007826 | Sustained release aminopyridine composition |
26 May, 2027
(2 years from now)
| Active |
| US8354437 | Method of using sustained release aminopyridine compositions |
22 Dec, 2026
(1 year, 11 months from now)
| Active |
| US8440703 | Methods of using sustained release aminopyridine compositions |
08 Apr, 2025
(3 months from now)
| Active |
| US8663685 | Sustained release aminopyridine composition |
18 Jan, 2025
(26 days from now)
| Active |
| US9918973 | Sustained release aminopyridine composition |
13 Dec, 2024
(9 days ago)
| Expired |
| US5540938 | Formulations and their use in the treatment of neurological diseases |
30 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ampyra's drug page
2. Cuvposa
Cuvposa is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7638552 | Method for increasing the bioavailability of glycopyrrolate |
20 Aug, 2023
(1 year, 4 months ago)
| Expired |
| US7816396 | Method for increasing the bioavailability of glycopyrrolate |
20 Aug, 2023
(1 year, 4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cuvposa's drug page
3. Inbrija
Inbrija is protected by 18 patents, out of which 13 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8545878 | Capsules containing high doses of levodopa for pulmonary use |
16 Nov, 2032
(7 years from now)
| Active |
| US8685442 | Capsules containing high doses of levodopa for pulmonary use |
16 Nov, 2032
(7 years from now)
| Active |
| US8945612 | Capsules containing high doses of levodopa for pulmonary use |
16 Nov, 2032
(7 years from now)
| Active |
| US9393210 | Capsules containing high doses of levodopa for pulmonary use |
16 Nov, 2032
(7 years from now)
| Active |
| USRE43711 | Pulmonary delivery for levodopa |
03 Feb, 2029
(4 years from now)
| Active |
| US7182961 | Particulate compositions for pulmonary delivery |
22 Feb, 2024
(9 months ago)
| Expired |
| US8404276 | Pulmonary delivery for levodopa |
19 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US8586093 | Pulmonary delivery for levodopa |
19 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US9155699 | Pulmonary delivery for levodopa |
19 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US7384649 | Particulate compositions for pulmonary delivery |
20 Nov, 2022
(2 years ago)
| Expired |
| US6858199 | High efficient delivery of a large therapeutic mass aerosol |
04 Nov, 2021
(3 years ago)
| Expired |
| US7556798 | Highly efficient delivery of a large therapeutic mass aerosol |
04 Nov, 2021
(3 years ago)
| Expired |
| US7146978 | Inhalation device and method |
16 Apr, 2021
(3 years ago)
| Expired |
| US6514482 | Pulmonary delivery in treating disorders of the central nervous system |
19 Sep, 2020
(4 years ago)
| Expired |
| US6613308 | Pulmonary delivery in treating disorders of the central nervous system |
19 Sep, 2020
(4 years ago)
| Expired |
| US6979437 | Pulmonary delivery in treating disorders of the central nervous system |
19 Sep, 2020
(4 years ago)
| Expired |
| US6921528 | Highly efficient delivery of a large therapeutic mass aerosol |
19 Jun, 2020
(4 years ago)
| Expired |
| US8628754 | Highly efficient delivery of a large therapeutic mass aerosol |
19 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inbrija's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List